Radiation Induced Brachial Plexopathy Clinical Trial
— PENTOCLOOfficial title:
Randomized Clinical Trial Evaluating Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy: the PENTOCLO Trial
| Verified date | December 2017 |
| Source | Assistance Publique - Hôpitaux de Paris |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Radiation-induced brachial plexopathy (RIP) is a rare and severe delayed peripheral nerve
complication of radiotherapy, that is spontaneously irreversible with no medical treatment to
limit or reduce symptoms. The investigators planed in RIP a randomized double blind clinical
trial, using a pentoxifylline (P)- tocopherol (E)- clodronate combination versus placebo, to
assess a possible symptomatic regression by a sensory-motor neurological quantifiable and
reproducible score (modified Subjective Objective Medical management Analytic, SOMA).
The investigators previously developed a successful PE treatment in symptomatic RI injuries
via the antioxidant pathway, in clinical phase II and III trails and experiments obtaining a
major significant radiation-induced fibrosis regression, then the PE clodronate combination
(PENTOCLO), obtaining a rapid and significant healing of mandible osteoradionecrosis and
significant neurological signs regression (- 35% modified SOMA score at 18 months) in 50
partial RIP.
The aim of this phase III randomized clinical trial is to show PENTOCLO efficiency and its
tolerance in long survival patients irradiated before for cancer and presenting with partial
RIP of upper or lower legs.
The investigators calculated to include 60 patients to show a significant clinical difference
between the two groups after 18 months of treatment: PENTOCLO[Pentoxifylline 400 (2x/d) +
vitamine E 500 (2x/d) + intermittent Clodronate 800 (2/d, 5d/7)] versus triple placebo, with
prednisone 20 (2d/7) for all patients.
RIP is assessed before treatment and every 6 months by a standardized sensory-motor
neurological (SOMA 95 modified by NCI-CTC 99) score used for main criteria at M18, and
various neurological scales of assessment (Visual Analog Scale for pain / VAS for
paresthesia, Neuropathic Pain Symptom Inventory [NPSI], Overall Disability Sum Score [ODSS],
muscle testing, Nine hole peg test / Timed 25-Foot Walk), quality of life (SF36, Patient
Global Impression of Change and Clinical Global impression of Change [PGIC/ CGIC]) and
electrophysiology.
| Status | Completed |
| Enrollment | 59 |
| Est. completion date | October 2017 |
| Est. primary completion date | May 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 74 Years |
| Eligibility |
Inclusion Criteria: - Past-history of post-operative or exclusive irradiation (RT) for currently in remission cancer, in particular - breast cancer with breast or thoracic anterior wall RT; axilla-subclavicular lymph nodes RT; sometimes lung or head/neck cancer - Lymphoma (Hodgkin or non Hodgkin) with axilla-subclavicular RT (upper limb) or lumbar-aortic (lower limbs) or testis tumor - Delay RT-RIP more than 6 months, but partial RIP - Neurological injury in irradiated volume confirmed by EMG - Patient living within distance compatible with day-hospitalization - Use of effective contraception for fertile women - Signed written informed consent (in case of motor paralysis informed consent is signed by a witness) Exclusion Criteria: - Localized or metastatic cancer recurrence (axillar MRI or PET scan) - Complete plexus injury with total motor paralysis of upper/ lower limb for more than 2 years - Associated neurological disease that may interferer with the assessment of endpoints - Hemorrhage, disease with hemorrhagic risk, unbalanced diabetes - Known hypersensitivity to Pentoxifylline, one of the excipients or biphosphonates - Renal failure, liver failure or decompensated heart failure - Taking another biphosphonate - Evolving virosis (hepatitis, herpes, zona) or live vaccine (influenza) - Uncontrolled psychotic condition - Informed consent not obtained - Fertile women who do not want or cannot use effective contraception during the administration of study drugs - Women pregnant or nursing |
| Country | Name | City | State |
|---|---|---|---|
| France | Groupe Hospitalier Pitié-Salpêtrière | Paris | |
| France | Hôpital Saint-Louis | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Assistance Publique - Hôpitaux de Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Sensory-motor neurological clinical assessment | Sensory-motor neurological clinical assessment of RIP patients as measured with SOMA scale (Subjective Objective Medical management Analytic involving tools) modified by NCI-CTC99 scale | 18 months | |
| Secondary | Pain VAS | Visual analog scale for pain | 6, 12, 18 months | |
| Secondary | NPSI scale | NPSI (Neuropathic Pain Symptom Inventory) pain scale to assess neuropathic pain by a self-questionnaire [Reference: Bouhassira et al. Development and validation of the neuropathic pain symptom inventory. Pain 2004;108(3):248-57] | 6, 12, 18 months | |
| Secondary | Paresthesia VAS | Visual analog scale for paresthesia | 6, 12, 18 months | |
| Secondary | Frequence of paresthesia | Evaluated on a 4-item scale: Never Occasional (several times each week or month) Intermittent (several times a day) Permanent (all day long and night) |
6, 12, 18 months | |
| Secondary | ODSS | Overall disability sum score: Checklist for upper limb (5 items) and lower limb (7 items) | 6, 12, 18 months | |
| Secondary | Muscle testing | Semi-quantitative manual muscle strength assessment on a 0 to 5 scale, separately for each muscle. | 6, 12, 18 months | |
| Secondary | Neurological examination | Evaluation of sensitivity, motricity and reflex | 6, 12, 18 months | |
| Secondary | Motor assessment of complex movements | Evaluated by two separate tests according to upper vs lower limb involvement: Nine Hole Peg test for brachial injury Timed 25-Foot Walk for lower limb symptoms |
6, 12, 18 months | |
| Secondary | Quality of life | Global quality of life as evaluated by SF36 questionnaire | 6, 12, 18 months | |
| Secondary | Global clinical impression | Patient global impression of change (PGIC) and clinical global impression of change (CGIC) | 6, 12, 18 months | |
| Secondary | Electromyography | Electromyography of upper / lower limbs | 6, 12, 18 months | |
| Secondary | Clinical symptoms evaluation | Clinical evaluation looking for upper digestive disorders (nausea, vomiting, epigastralgia), lower digestive disorders (diarrhea), vascular disorders (cephalalgia, vertigo, flush, deep asthenia), bleeding (hematoma) | 6, 12, 18 months | |
| Secondary | Biological evaluation | evaluation of biological parameters: blood cell count, platelets, sedimentation velocity, C-reactive protein, prothrombin time, TCK, calcemia, protidemia, LDH, creatininemia, phosphokinase creatine (CPK) | 6, 12, 18 months | |
| Secondary | Cardiovascular evaluation | As evaluated by: Heart rate Blood pressure lying and standing after 5 minutes orthostatism Electrocardiogramm |
6, 12, 18 months |